Peter Wehrwein, Managing Editor

A growing mistrust of medical providers could be traced back to doubts about scientific validity and treatment costs, according to Luke Hansen, M.D., M.H.S., chief medical officer of Arcadia, a healthcare data analytics company.

Employers and Medicare trustees could come together and change the healthcare industry, leading to healthcare reform, according to Luke Hansen, M.D., M.H.S., and chief medical officer of Arcadia, a healthcare data analytics company.

Luke Hansen, M.D., M.H.S., chief medical officer of Arcadia, a healthcare data analytics company, explains that the Make America Healthy Again initiative’s focus on chronic disease support will benefit value-based care and preventative care.

Moving away from accountable care organizations (ACOs) will not lead to value-based care, according to Luke Hansen, M.D., M.H.S., and chief medical officer of Arcadia, a healthcare data analytics company.

Luke Hansen, M.D., M.H.S., and chief medical officer of Arcadia, a healthcare data analytics company, said that achieving value-based care will need to be a multipronged approach with commercial purchasers and state Medicaid programs playing a prominent role.

An overview of Arcadia, a healthcare data analytics company, according to chief medical officer, Luke Hansen, M.D., M.H.S.

At a Senate confirmation hearing for CMS administrator, Mehmet Oz, M.D., would not answer directly whether he would support budget cuts to the Medicaid program.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded those from the twice-yearly dosing.

A Columbia University dermatologist argues that physicians in her specialty should be on the lookout for metabolic syndrome and obesity — and treat it.

Reaching out to waitlisted patients and organizing the staff into high-volume teams for a week shrank the waitlist from more than 3,000 unseen patients to 300.

A reduction in emergency room visits is just one of the ways teledermatology has improved patient outcomes and reduced costs, according to Elizabeth K. Jones, M.D., an associate dermatology professor at Thomas Jefferson University Hospital in Philadelphia.

An overview of the definition of teledermatology and it’s three subtypes, according to Elizabeth K. Jones, M.D., FAAD, an associate dermatology professor at Thomas Jefferson University Hospital.

Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the 2025 meeting of the Amercian Academy of Dermatology.

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in another similar study, which had high favorable response rate in the placebo group.

Rebecca Vasquez, M.D., FAAD, said that while there is not enough data to support success stories yet, she has seen firsthand the ways addressing social drivers of health has impacted her patients.

Raising funding for research on social drivers of health may become an obstacle, given recent anti-DEI policies put into place by the federal government, according to Rebecca Vasquez, M.D., FAAD, a speaker at the 2025 American Academy of Dermatology meeting.

The advent of remibrutinib, a Bruton's tyrosine kinase inhibitor, may encourage dermatologists to take care of chronic spontaneous urticaria patients, says a presenter at the 2025 meeting of the American Academy of Dermatology.

Markary, a surgeon at Johns Hopkins, gave safe, vague and polished answers to senators' questions on mifepristone and the cancellation of an FDA vaccine committee meeting.

Progressive pulmonary fibrosis is not a diagnosis so much as a disease behavior and a clinical phenotype, says Anna-Maria Hoffmann-Vold, M.D., Ph.D., of Oslo University Hospital and the expert featured on this MHE K-Cast.

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has developed are mixed.

Approximately 70 minutes into the address, President Donald Trump mentioned rising childhood cancer rates and the prevalence of autism.

Major Medicaid cuts may be overshadowing work requirements, but they remain a priority for Republicans. Work requirements are “bad health policy,” says Leanne Berge, J.D., CEO of the Community Health Plan of Washington, although they would not have as great an impact as the cuts that have been under discussion.

Six takeaways from a recent review about the brain-related comorbidities of Duchenne muscular dystrophy

Medicaid is a needs-based program, but the misconception that it is a program solely for poor people has made it a target for large federal budget cuts, says Leanne Berge, CEO of a not-for-profit health plan in Washington state.

But major cuts to federal for Medicaid are a likely outcome of the $1.5-$2 trillion in spending cuts over the next 10 years that the Republican-backed budget resolution calls for.

Unlike some other spending cuts, Medicaid cuts will have direct impact on people who voted for Republicans in November 2024, according to Leanne Berge, health plan leader

The Advisory Committee on Immunization Practices (ACIP) that makes recommendations to the Centers for Disease Control and Prevention had been scheduled to meet next week.

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B inhibitor as a treatment for progressive pulmonary fibrosis.